A PNPLA3–NACC1–RIPK3 pathway mediates macrophage necroptosis and inflammation in MASLD
Open Access
- 21 January 2026
- journal article
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (2)
Abstract
Background: The 148M variant of PNPLA3 is a major genetic risk factor for metabolic dysfunction–associated steatotic liver disease (MASLD), yet its macrophage-specific role remains unclear. We investigated how PNPLA3-148M alters macrophage behavior and multicellular liver pathology under lipotoxic stress. Methods: We used a human induced pluripotent stem cell (iPSC)-derived multicellular liver culture comprising hepatocytes, hepatic stellate cells (HSCs), and isogenic macrophages that differed only at PNPLA3 (148M vs. 148I). Cultures were exposed to lipotoxic conditions to induce MASLD. We quantified inflammatory cytokines, oxidative stress, hepatocyte lipid accumulation, and HSC activation. Macrophage death pathways were profiled (apoptosis, pyroptosis, necroptosis), with emphasis on RIPK3 expression and phosphorylation. Downstream effects on hepatocytes and HSCs were assessed. Results: Under lipotoxic stress, 148M macrophages amplified MASLD-like features. PNPLA3 transcripts were induced in macrophages—rising in iPSC-derived macrophages from lipotoxic cultures, and in Kupffer cells isolated from murine MASLD. Single-cell RNA-seq further confirmed PNPLA3 expression in human liver macrophage clusters, in addition to hepatocytes and HSCs. Although PNPLA3 mRNA was comparable between genotypes, 148M macrophages displayed higher PNPLA3 protein and increased necroptosis, evidenced by elevated RIPK3 expression and phosphorylation without changes in apoptosis or pyroptosis. Integrative analyses identified NACC1 as a key transcriptional regulator of RIPK3 , with NF-κB–linked upregulation of NACC1 in 148M macrophages. NACC1 inhibition (genetic or NIC3) reduced RIPK3, suppressed necroptosis, and lowered pro-inflammatory cytokine secretion. NIC3 additionally decreased hepatocyte lipid accumulation and ATP and diminished HSC activation markers. Conclusions: The PNPLA3 148M variant promotes MASLD through a macrophage-specific NF-κB–NACC1–RIPK3 axis that enhances necroptosis and inflammatory signaling, thereby exacerbating hepatocyte steatosis and HSC activation. NACC1 emerges as a tractable therapeutic target for genetically at-risk individuals.Keywords
This publication has 25 references indexed in Scilit:
- The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver DiseaseCurrent Obesity Reports, 2023
- IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver diseaseJournal of Hepatology, 2022
- Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage nichesCell, 2022
- Mechanisms and disease consequences of nonalcoholic fatty liver diseaseCell, 2021
- The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylationHepatology, 2017
- PNPLA3 gene in liver diseasesJournal of Hepatology, 2016
- Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosisHepatology, 2014
- Adiponutrin Functions as a Nutritionally Regulated Lysophosphatidic Acid AcyltransferaseCell Metabolism, 2012
- Assessing the data quality in predictive toxicology using a panel of cell lines and cytotoxicity assaysAnalytical Biochemistry, 2007
- SREBP transcription factors: master regulators of lipid homeostasisBiochimie, 2004